Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy
Copyright © 2022 Elsevier Inc. All rights reserved..
Immune checkpoint blockade (ICB) can produce durable responses against cancer. We and others have found that a subset of patients experiences paradoxical rapid cancer progression during immunotherapy. It is poorly understood how tumors can accelerate their progression during ICB. In some preclinical models, ICB causes hyperprogressive disease (HPD). While immune exclusion drives resistance to ICB, counterintuitively, patients with HPD and complete response (CR) following ICB manifest comparable levels of tumor-infiltrating CD8+ T cells and interferon γ (IFNγ) gene signature. Interestingly, patients with HPD but not CR exhibit elevated tumoral fibroblast growth factor 2 (FGF2) and β-catenin signaling. In animal models, T cell-derived IFNγ promotes tumor FGF2 signaling, thereby suppressing PKM2 activity and decreasing NAD+, resulting in reduction of SIRT1-mediated β-catenin deacetylation and enhanced β-catenin acetylation, consequently reprograming tumor stemness. Targeting the IFNγ-PKM2-β-catenin axis prevents HPD in preclinical models. Thus, the crosstalk of core immunogenic, metabolic, and oncogenic pathways via the IFNγ-PKM2-β-catenin cascade underlies ICB-associated HPD.
| Errataetall: |
CommentIn: Cancer Cell. 2023 Feb 13;41(2):229-231. - PMID 36787694 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Cancer cell - 41(2023), 2 vom: 13. Feb., Seite 304-322.e7 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, Gaopeng [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 16.02.2023 Date Revised 14.02.2024 published: Print-Electronic CommentIn: Cancer Cell. 2023 Feb 13;41(2):229-231. - PMID 36787694 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ccell.2022.12.008 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351497242 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351497242 | ||
| 003 | DE-627 | ||
| 005 | 20240214232628.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ccell.2022.12.008 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1292.xml |
| 035 | |a (DE-627)NLM351497242 | ||
| 035 | |a (NLM)36638784 | ||
| 035 | |a (PII)S1535-6108(22)00594-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Li, Gaopeng |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.02.2023 | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Cancer Cell. 2023 Feb 13;41(2):229-231. - PMID 36787694 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier Inc. All rights reserved. | ||
| 520 | |a Immune checkpoint blockade (ICB) can produce durable responses against cancer. We and others have found that a subset of patients experiences paradoxical rapid cancer progression during immunotherapy. It is poorly understood how tumors can accelerate their progression during ICB. In some preclinical models, ICB causes hyperprogressive disease (HPD). While immune exclusion drives resistance to ICB, counterintuitively, patients with HPD and complete response (CR) following ICB manifest comparable levels of tumor-infiltrating CD8+ T cells and interferon γ (IFNγ) gene signature. Interestingly, patients with HPD but not CR exhibit elevated tumoral fibroblast growth factor 2 (FGF2) and β-catenin signaling. In animal models, T cell-derived IFNγ promotes tumor FGF2 signaling, thereby suppressing PKM2 activity and decreasing NAD+, resulting in reduction of SIRT1-mediated β-catenin deacetylation and enhanced β-catenin acetylation, consequently reprograming tumor stemness. Targeting the IFNγ-PKM2-β-catenin axis prevents HPD in preclinical models. Thus, the crosstalk of core immunogenic, metabolic, and oncogenic pathways via the IFNγ-PKM2-β-catenin cascade underlies ICB-associated HPD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a FGF2 | |
| 650 | 4 | |a IFNγ | |
| 650 | 4 | |a PD-L1/PD-1 pathway | |
| 650 | 4 | |a T cell immunity | |
| 650 | 4 | |a complete response | |
| 650 | 4 | |a glycolytic metabolism | |
| 650 | 4 | |a hyperprogressive disease | |
| 650 | 4 | |a immune checkpoint blockade | |
| 650 | 4 | |a oncogenesis | |
| 650 | 4 | |a β-catenin | |
| 650 | 7 | |a beta Catenin |2 NLM | |
| 650 | 7 | |a Fibroblast Growth Factor 2 |2 NLM | |
| 650 | 7 | |a 103107-01-3 |2 NLM | |
| 650 | 7 | |a Interferon-gamma |2 NLM | |
| 650 | 7 | |a 82115-62-6 |2 NLM | |
| 700 | 1 | |a Choi, Jae Eun |e verfasserin |4 aut | |
| 700 | 1 | |a Kryczek, Ilona |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Yilun |e verfasserin |4 aut | |
| 700 | 1 | |a Liao, Peng |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Shasha |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Shuang |e verfasserin |4 aut | |
| 700 | 1 | |a Grove, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Vatan, Linda |e verfasserin |4 aut | |
| 700 | 1 | |a Nelson, Reagan |e verfasserin |4 aut | |
| 700 | 1 | |a Schaefer, Grace |e verfasserin |4 aut | |
| 700 | 1 | |a Allen, Steven G |e verfasserin |4 aut | |
| 700 | 1 | |a Sankar, Kamya |e verfasserin |4 aut | |
| 700 | 1 | |a Fecher, Leslie A |e verfasserin |4 aut | |
| 700 | 1 | |a Mendiratta-Lala, Mishal |e verfasserin |4 aut | |
| 700 | 1 | |a Frankel, Timothy L |e verfasserin |4 aut | |
| 700 | 1 | |a Qin, Angel |e verfasserin |4 aut | |
| 700 | 1 | |a Waninger, Jessica J |e verfasserin |4 aut | |
| 700 | 1 | |a Tezel, Alangoya |e verfasserin |4 aut | |
| 700 | 1 | |a Alva, Ajjai |e verfasserin |4 aut | |
| 700 | 1 | |a Lao, Christopher D |e verfasserin |4 aut | |
| 700 | 1 | |a Ramnath, Nithya |e verfasserin |4 aut | |
| 700 | 1 | |a Cieslik, Marcin |e verfasserin |4 aut | |
| 700 | 1 | |a Harms, Paul W |e verfasserin |4 aut | |
| 700 | 1 | |a Green, Michael D |e verfasserin |4 aut | |
| 700 | 1 | |a Chinnaiyan, Arul M |e verfasserin |4 aut | |
| 700 | 1 | |a Zou, Weiping |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer cell |d 2002 |g 41(2023), 2 vom: 13. Feb., Seite 304-322.e7 |w (DE-627)NLM119589826 |x 1878-3686 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2023 |g number:2 |g day:13 |g month:02 |g pages:304-322.e7 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ccell.2022.12.008 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2023 |e 2 |b 13 |c 02 |h 304-322.e7 | ||